sensation of throat closing, prolonged wheezing, shortness of breath and chest pain; sensation of throat closing, prolonged wheezing, shortness of breath and chest pain; sensation of throat closing, prolonged wheezing, shortness of breath and chest pain; sensation of throat closing, prolonged wheezing, shortness of breath and chest pain; This spontaneous case was reported by a physician and describes the occurrence of WHEEZING (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain), DYSPNOEA (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain), CHEST PAIN (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) and OROPHARYNGEAL DISCOMFORT (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Asthma and Sulfonamide allergy (allergic to sulfa medications).   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced WHEEZING (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) (seriousness criterion medically significant), DYSPNOEA (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) (seriousness criterion medically significant), CHEST PAIN (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) (seriousness criterion medically significant) and OROPHARYNGEAL DISCOMFORT (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) (seriousness criterion medically significant). The patient was treated with EPINEPHRINE (EPIPEN) for Throat discomfort, at an unspecified dose and frequency. At the time of the report, WHEEZING (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain), DYSPNOEA (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain), CHEST PAIN (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) and OROPHARYNGEAL DISCOMFORT (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered WHEEZING (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain), DYSPNOEA (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain), CHEST PAIN (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) and OROPHARYNGEAL DISCOMFORT (sensation of throat closing, prolonged wheezing, shortness of breath and chest pain) to be related.    No concomitant medication details was reported. After her vaccine dose, she felt like throat was closing and used her epipen. There was no relief so she was treated at the ER. She also experienced wheezing, shortness of breath and chest pain. She is allergic to sulfa  medications. She continues to have these symptoms almost 8 months later. She has seen multiple specialists including pulmonologist, cardiologist, allergist. She is not improved with asthma treatment. Further testing was unrevealing.  This case concerns a 40-year-old, female patient with previous relevant medical history of asthma and sulfonamide allergy, who experienced the unexpected events of wheezing, dyspnoea, chest pain and oropharyngeal discomfort. The events occurred on an unknown number of days after the second dose of mRNA-1273. The rechallenge was not applicable since the events happened after the second dose. The medical history of asthma and sulfonamide allergy remains a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This case concerns a 40-year-old, female patient with previous relevant medical history of asthma and sulfonamide allergy, who experienced the unexpected events of wheezing, dyspnoea, chest pain and oropharyngeal discomfort. The events occurred on an unknown number of days after the second dose of mRNA-1273. The rechallenge was not applicable since the events happened after the second dose. The medical history of asthma and sulfonamide allergy remains a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report. t.